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Abstract
Background: Children with very early-onset inflammatory bowel disease (VEO-IBD), those diagnosed at less than
5 years of age, are a unique population. A subset of these patients present with a distinct phenotype and more
severe disease than older children and adults. Host genetics is thought to play a more prominent role in this
young population, and monogenic defects in genes related to primary immunodeficiencies are responsible for
the disease in a small subset of patients with VEO-IBD.
Case Presentation: We report a child who presented at 3 weeks of life with very early-onset inflammatory bowel
disease (VEO-IBD). He had a complicated disease course and remained unresponsive to medical and surgical therapy.
The refractory nature of his disease, together with his young age of presentation, prompted utilization of whole exome
sequencing (WES) to detect an underlying monogenic primary immunodeficiency and potentially target therapy to the
identified defect. Copy number variation analysis (CNV) was performed using the eXome-Hidden Markov Model. Whole
exome sequencing revealed 1,380 nonsense and missense variants in the patient. Plausible candidate variants were not
detected following analysis of filtered variants, therefore, we performed CNV analysis of the WES data, which led us to
identify a de novo whole gene deletion in XIAP.
Conclusion: This is the first reported whole gene deletion in XIAP, the causal gene responsible for XLP2 (X-linked
lymphoproliferative Disease 2). XLP2 is a syndrome resulting in VEO-IBD and can increase susceptibility to
hemophagocytic lymphohistocytosis (HLH). This identification allowed the patient to be referred for bone
marrow transplantation, potentially curative for his disease and critical to prevent the catastrophic sequela of HLH.
This illustrates the unique etiology of VEO-IBD, and the subsequent effects on therapeutic options. This cohort requires
careful and thorough evaluation for monogenic defects and primary immunodeficiencies.
Keywords: VEO-IBD (very early-onset IBD), XIAP (x-linked inhibitor of apoptosis), XLP2 (X-linked lymphoproliferative
Disease 2), WES (whole exome sequencing)
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Background
Primary immunodeficiencies are a heterogeneous group
of disorders that range in severity and clinical presenta-
tion, and may also lead to immune dysregulation such as
severe inflammatory bowel disease (IBD), most frequently
in patients with very early-onset IBD (VEO-IBD). VEO-
IBD presents with a unique phenotype, including severe
disease that is often unresponsive to conventional therap-
ies. Disease causing variants have been detected in IL-10,
IL-10R [1–4], CYBB, CYBA, NCF1, NCF2 and NCF4
(chronic granulomatous disease), FOXP3, WAS, MEFV,
ITGB2, as well as other genes in patients with severe
VEO-IBD [3, 5–7]. In addition, mutations have been iden-
tified in X-linked inhibitor of apoptosis (XIAP) in patients
with VEO-IBD [8]. While defects in the gene SH2D1A
were initially detected in patients with X-linked lympho-
proliferative disease, known as XLP1 [9, 10], mutations in
XIAP result in XLP2 [11]. IBD can be the first and only
feature of XLP2. We report here a case of a male who pre-
sented in the neonatal period with severe refractory IBD,
without any evidence of immunodeficiency, and was
found to have a de novo whole gene deletion of XIAP at
age 17. This is the first reported whole gene deletion
identified in the literature and illustrates the unique
pathogenesis of disease in children with VEO-IBD.
Case Presentation
The patient presented with VEO-IBD at 3 weeks of life
with severe, bloody diarrhea. His initial endoscopy and
colonoscopy, performed at 8 weeks, demonstrated upper
tract disease (gastric and duodenal) and severe pancoli-
tis. At 5 months of age, he developed a perianal sinus
tract. He was initially treated with Azulfidine, steroids
and elemental formula. The patient was unable to
tolerate oral feeds and was thus TPN (total parental
nutrition) dependent. He continued to have profound
growth failure (<5 %) and due to lack of response to the
addition of antibiotics and enemas to his regimen, a G-
tube was placed and Azathioprine was initiated. His
course remained severe, complicated by pathological
vertebral fracture. Repeat endoscopy at 2 years of age
demonstrated severe upper tract disease and worsening
colonic disease. His perianal disease progressed as well,
with abscess and fistula formation. At approximately
4 years of age he was found to have a distal rectal stric-
ture requiring repeated dilations. He was initiated on
infliximab at 5 years of age in addition to azathioprine as
dual therapy, which was changed to methotrexate a year
later. At 7 years of age, during a rectal dilation he devel-
oped a colonic perforation and required a diverting
ileostomy. The patient continued to be medically refrac-
tory, therefore, when he was 10 years old he underwent
a colectomy. Post-operatively, his disease remained se-
vere, and was unresponsive to medical therapy, including
adalimumab, methotrexate, antibiotics, IVIG and finally
vedolizumab, Repeat endoscopy performed demon-
strated duodenal stricture and severe ileal disease
(Fig. 1). In addition, the patient developed recurrent
skin and intestinal abscesses and had significant steroid
exposure throughout this time.
This patient’s young age at diagnosis and progressive
disease severity prompted an immunologic evaluation
to detect primary immunodeficiencies associated with
VEO-IBD. At age 16, further studies including quanti-
tative immunoglobulins, vaccine titers, B and T cell
lymphocyte subset analysis, natural killer (NK) cells,
and toll like receptors were obtained. He was found to
have normal levels of circulating T cells, but mildly low
subsets of NK cells. His B cells exhibited activation as
detected by CD80 expression and he had increased
plasmablasts (4 %) and low IgM memory B cells (3 %).
In addition, when he was 17 years old, after written
informed consent was obtained from his parents and
assent from the patient, the patient and his family were
recruited in the VEO-IBD research study using whole
exome sequencing (WES) to detect rare or novel vari-
ants that contribute to disease at our institution.
Exome sequencing of the patient and his mother were
performed under protocol 2002-07-2805 that was ap-
proved by the Institutional Review Board at The Chil-
dren’s Hospital of Philadelphia (CHOP). Exome capture
was performed using the Agilent SureSelect V4 kit then
sequenced using the Illumina HiSeq sequencer at an aver-
age coverage depth of 100X. Paired-end reads were
aligned to the human reference genome GRCh37.p10
using Novoalign (V2.07.18; http://www.novocraft.com).
Variants were detected using The Broad Institute’s GATK
[12] best practices, then annotated using SNPEff [13],
1000 Genomes Project (www.1000genomes.org/), Exome
Variant Server (EVS) (http://evs.gs.washington.edu/EVS/),
the Exome Aggregation Consortium (ExAC) (http://
exac.broadinstitute.org; release 0.3), and the Combined
Annotation-Dependent Depletion tool (CADD) [14].
Identified variants were then filtered, retaining only
nonsynonymous missense and nonsense, rare (minor
allele frequency <0.1 % in all 3 databases) or novel
mutations, with a CADD score ≥10. Variants were
further restricted to genes involved in primary im-
munodeficiency. Copy number variation (CNV) ana-
lysis was performed using the eXome-Hidden Markov
Model (XHMM) [15].
Genotyping was conducted using the Illumina
HumanHap550v3.0 Beadchip. The data was analyzed
using Beadstudio software (Illumina) to confirm the
deletion that was found in the WES data.
The XIAP CNV was confirmed using the Bio-Rad
QX100 droplet digital PCR (ddPCR) platform. Prede-
signed primer/probe configurations were used for XIAP
Kelsen et al. BMC Gastroenterology  (2015) 15:160 Page 2 of 5
(cat#: Hs04517714_cn) and the reference gene TERT
(cat#4403326). Standard ddPCR conditions and analysis
methods were used for this assay [16].
Whole exome sequencing revealed 1,380 nonsense and
missense variants in the patient. However, after restrict-
ing the variants to rare or novel variants in genes associ-
ated with immunodeficiency, only a single variant was
identified in CCHCR1 (p.Gln609Pro) that met our cri-
teria. The same variant was also found in the patient’s
unaffected mother and therefore was unlikely to be
associated with his disease.
We then performed CNV analysis of the WES data of the
patient and his mother, which led us to identify a de novo
whole gene deletion in XIAP (Fig. 2a). The deletion was
then validated using both SNP arrays and ddPCR (Fig. 2b).
The SNP array deletion spanned from rs5958318 at pos-
ition chrX:122,992,832, near the 5’ end to rs10521711 at
position chrX:123,047,926 near the 3’ UTR of XIAP, which
confirmed that the entire gene was deleted.
Functional analysis of XIAP demonstrated lack of
XIAP expression in CD4+ and CD8+ T cells, NK cells
and B cells. Following identification of this deletion the
patient was referred to our Bone Marrow Transplant
Team for a bone marrow transplantation (BMT).
Discussion
Monogenic defects of primary immunodeficiency can
present as severe neonatal IBD, including epithelial bar-
rier defects, phagocyte defects (Chronic granulomatous
disease, defects of NADPH oxidase LAD), B and T cell
abnormalities (Severe combined immunodeficiency,
common variable immunodeficiency, Wiskott-Aldrich
Syndrome, immunodysregulation polyendocrinopathy
enteropathy X-linked syndrome), autoimmunity (including
XLP2) and IL-10R defects. Due to this patient’s severe
refractory disease and age of onset, evaluation for primary
immunodeficiency was performed. Although the immune
work up was unrevealing, evaluation of WES data demon-
strated a whole gene deletion of XIAP.
X-linked lymphoproliferative disease, XLP1, first de-
scribed in 1974 by Purtilio, results in the immunodefi-
ciency of severe susceptibility to EBV due to defects in
NK cell mediated toxicity, and leads to hemophagocytic
lymphohistocytosis (HLH), dysgammaglobulimemia and
lymphoma [17]. This triad is secondary to inactivating
mutations in SH2D1A, encoding SLAM-associated pro-
tein (SAP), on chromosome Xq25 [10]. In 2006, Rigaud
et al. demonstrated that mutations in the gene that
encodes the X-linked inhibitor-of-apoptosis XIAP (also
termed BIRC4) resulted in another X-linked lymphopro-
liferative syndrome, XLP2, distinct from SAP deficiency
XLP (XLP1) [11]. The immune dysregulation in these
patients, including our patient described here, was char-
acterized by absent XIAP in lymphocytes, NK cells and
Fig. 1 Endoscopy images: (a) duodenal narrowing; Ileoscopy: (b)
and (c) Ulcerations and inflammation of the ileum
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myeloid cells. Two of the patients described by Riguard
had hemizygous mutations in XIAP and developed IBD.
Worthey et al. first identified XIAP deficiency in VEO-
IBD, in a 15-month-old male with severe fistulizing
Crohn’s disease. This patient had a novel hemizygous
mutation and ultimately underwent BMT, which proved
to be curative [8]. Since then, several other cases of
XIAP missense or nonsense mutations in patients with
VEO-IBD have been reported [18]. Zeissig et al. further
demonstrated the role of XIAP deficiency in severe
VEO-IBD, with the identification of variants in 4 male
pediatric patients, ages 1–16 [18]. The variant identified
in the patient described in this study is the first whole
gene deletion, to our knowledge, to be reported in VEO-
IBD, and its identification provided a potentially curative
therapeutic option. The mapping of the deletion de-
scribed in this study compared to mutations previously
reported in the literature in association with IBD is
depicted in Fig. 2c.
The inhibitors of apoptosis (IAPs) genes, such as XIAP,
are instrumental for both innate and adaptive immunity.
XIAP inhibits apoptosis in activated T cells, thus allowing
expansion and survival via blockade of initiator and ef-
fector caspases [19] or through binding to death-inducing
caspases and subsequent proteosomal mediated degrad-
ation. IAPs contain 1–3 baculoviral IAP repeat (BIR)
homology domains, a ubiquitin binding domain (UBA)
and a C-terminal RING domain [20]. BIR2 and BIR3 do-
mains of cIAP1, CIAP2 and XIAP are required for binding
to and suppression of specific cell death-inducing caspases
[19]. XIAP inhibits apoptosis by binding to and blocking
activated forms of caspases 3,7 and 9. XIAP participates in
innate immunity through signaling pathways and cellular
responses via ubiquitin ligases activity [20]. It is required
in the signaling and function of the pattern recognition re-
ceptors, NOD1, NOD2 and Dectin-1 [19]. Upon activation
during infection, NOD1/2 and Dectin-1 promote cytokine
production, with subsequent clearance of pathogens. XIAP
is also involved in the inhibitory signaling of inflamma-
somes (NLRP3 in murine models) and decreases TNF-α
activation by pathogen-associated molecular patterns
(PAMPs). Therefore, XIAP eradicates local acute inflam-
mation and maintains low levels of baseline inflammation.
In XIAP-deficient patients, both arms of the immune
system, innate and adaptive responses, are affected, with a
cyclical environment of unchecked activation of inflam-
masomes and intestinal permeability to pathogens leading
to the accumulation of pro-inflammatory cytokines such
as TNF-α, IL-1β and IL-18. Finally, there is increased cell-
death of cells, including lymphocytes and myeloid cells
and chronic inflammation. Ultimately the patient develops
the phenotype of splenomegaly, IBD and HLH [20].
Fig. 2 XIAP whole gene deletion. a Depth of coverage of XIAP exons from whole exome sequencing data in the proband, his mother (green), a
female control (blue) and a male control (purple). The red box indicates missing coverage for XIAP exons in the proband. b Copy number analysis of
XIAP using ddPCR shows gene deletion in the proband compared to control males (purple) and females (blue). c Location of the XIAP whole gene
deletion (bold) and previously reported XIAP mutations associated with IBD across the 6 coding exons of XIAP. *Exon numbers adjusted to reflect
coding exons of XIAP
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Conclusion
Due to the extensive differential in the work up of our pa-
tient with severe VEO-IBD, next generation sequencing
technology can be of benefit. Targeted sequencing, to
evaluate for identified monogenic defects in VEO-IBD, or
WES to study the whole exome, can offer a quicker
method of analysis rather than a gene-by-gene approach.
The results of this critical finding directed the course of
action of treatment. Because XIAP deficiency has a high
risk of fatal HLH, and due to his severe disease, he has
undergone bone marrow transplantation. While XLP2
functional analysis currently exists, the wide differential in
this case made WES, and the multidisciplinary approach
involving gastroenterology, genetics, immunology and
bioinformatics an attractive and effective option.
Consent
Written informed consent was obtained from the patient’s
parents as he is a minor, for publication of this Case report
and any accompanying images. A copy of the written con-
sent is available for review by the Editor of this journal.
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